Atossa Genetics Inc.

The momentum for this stock is not very good. Atossa Genetics Inc. is not very popular among insiders. Atossa Genetics Inc. is a mediocre stock to choose.
Log in to see more information.
Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the deve...

News

Atossa Therapeutics announces support of final rule from FDA
Atossa Therapeutics announces support of final rule from FDA

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Globe Newswire FDA Update to Mammography Regulations in MQSA Final Rule is Effective TodaySEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today...\n more…

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire SEATTLE, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ( Atossa or the Company ), today announced its participation in the H.C. Wainwright 26th Annual Global...\n more…

Atossa Therapeutics granted U.S. patent for endoxifen
Atossa Therapeutics granted U.S. patent for endoxifen

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Globe Newswire SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ( Atossa or the Company ), today announced that the United States Patent and Trademark Office (USPTO) has...\n more…

When Can We Expect A Profit From Atossa Therapeutics, Inc. (NASDAQ:ATOS)?
When Can We Expect A Profit From Atossa Therapeutics, Inc. (NASDAQ:ATOS)?

Simply Wall St We feel now is a pretty good time to analyse Atossa Therapeutics, Inc.'s ( NASDAQ:ATOS ) business as it appears the...\n more…